HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained a $92 price target.

May 08, 2024 | 7:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals receives a reiterated Buy rating and a maintained $92 price target from HC Wainwright & Co.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. can positively influence investor sentiment and potentially lead to an increase in stock price in the short term. The specific mention of Apellis Pharmaceuticals and the reaffirmation of a $92 price target underscore the firm's confidence in the company's prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100